- April 25, 2013
DELAWARE CITY, DE | Bilcare Research, a manufacturer of mono- and multi-layer barrier films and foils for the pharmaceutical industry, reports the introduction of a modern, high-speed lamination line for the production of Aclar multilayer films and Triplex PVdC films at its Bötzingen facility in Germany.
The investment, along with the expansion of PVdC coating capacities in the Singapore facility, provides Bilcare Research with added capabilities toward meeting increasing demands in the North American market. Company says these investments position it for global manufacturing redundancy of Aclar lamination and PVdC coating capabilities by having multiple global locations to support North American customers in a more enhanced cost position from its US facility.
Company says its range of Aclar laminates provides very high moisture barrier and are crystal clear, biochemically inert, chemical-resistant, non-flammable, and free of plasticizers and stabilizers. Company also is introducing Aclar laminates with features that create unique identities to pharmaceutical brands, said to provide protection from similar “me too” products.
“This investment in our new laminating line is the latest component of our continued growth strategy to meet the needs of rapidly evolving business models in the global pharmaceutical industry," says Thorsten Kühn, CEO of Bilcare Research AG, Switzerland. "We see increased demand across our entire range of Bilcare Aclar laminates, from both innovator and generic pharmaceutical companies."